Publications

2012

• GJ. Bernardes, G. Casi, S. Trüssel, I. Hartmann, K. Schwager, J. Scheuermann, D. Neri (2012) “A traceless vascular-targeting antibody-drug conjugate for cancer therapy” Angew Chem Int Ed Engl. 2012 Jan 23;51(4):941-4. doi: 10.1002/anie.201106527
• K. Galle, K. Junker, M. Franz, J. Hentschel, P. Richter, M. Gajda, A. Göhlert, F. von Eggeling, R. Heller, R. Giavazzi, D. Neri, H. Kosmehl, H. Wunderlich, A. Berndt (2012) “Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery” Histochem Cell Biol. 2012 Feb;137(2):195-204.

2011

• M. Franz, D. Neri, A. Berndt (2011) “Chronic cardiac allograft rejection: critical role of ED-A(+) fibronectin and implications for targeted therapy strategies” J Pathol. 2011 Nov 21. doi: 10.1002/path.3968.
• L. Mannocci, M.Leimbacher, M. Wichert, J. Scheuerman, D. Neri (2011) “20 years of DNA-encoded chemical libraries”, Chem Commun (Camb). 2011 Dec 28;47(48):12747-53.
• N. Pasche, K.D. Frey, D. Neri (2011) “The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate”. Angiogenesis. 2011 Nov 4
• T.K. Eigentler, B. Weide, F. de Braud, G. Spitaleri, A. Romanini, A. Pflugfelder, R. Gonzales-Iglesias , A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato, M. Kaspar, E. Trachsel, H.D. Menssen, D. Neri, C. Garbe (2011) “A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.” Clin Cancer Res. 2011 Dec 15;17(24):7732-42.
• T. Gecks, K. Junker, M. Franz, P. Richter, M. Walther, Voigt, D. Neri, H. Kosmehl, H. Wunderlich, M. Kiehntopf, A. Berndt (2011) “B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder?” Clin. Chim. Acta., 412, 1931-1936.
• M. Pedretti, C. Verpelli, J. Mårlind, G. Bertani, C. Sala, D. Neri*, L. Bello (2010) “Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma”. Br. J. Cancer, in press [* = corresponding author].
• K. Schwager, F. Bootz, P. Imesch, M. Kaspar, E. Trachsel, D. Neri (2011) “The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model”. Hum. Reprod., 26, 2344-2352.
• K. Schwager, A. Villa, C. Rösli, D. Neri, M. Rösli-Khabas, G. Moser (2011) “A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer”. Head Neck Oncol., 3, 25
• D. Neri and C. Supuran (2011) “New drugs interfering with pH regulation in tumors”. Nature Rev. Drug Discov., 10, 767-777
• M. Steiner and D. Neri (2011) “Antibody-radionuclide conjugates for cancer therapy: historical perspectives and new trends”. Clin. Cancer Res., 17, 6406-6416
• N. Pasche, J. Woytschak, K. Frey, S. Wulhfard, A. Villa, D. Neri (2011) “Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7”. J. Biotechnol., 154, 84-92.
• A.Villa, V. Lovato, E. Bujak, S. Wulhfard, N. Pasche, D. Neri (2011) “A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin”. MAbs, 3, 264-272.
• A. Palumbo, F. Hauler, P. Dziunycz, K. Schwager, A. Soltermann, F. Pretto, C. Alonso, G.F. Hofbauer, R.W. Boyle, D. Neri (2011) “A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels”. Br. J. Cancer, 104, 1106-1115
• M. Czabanka, G. Parmaksiz, S.H. Bayerl, M. Nieminen, E. Trachsel, H.D. Menssen, R. Erber, D. Neri, P. Vajkoczy (2011) “Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies”. Eur. J. Cancer, 47, 1276-1284.
• K. Frey, M. Fiechter, K. Schwager, B. Belloni, M. Barysch, D. Neri, R. Dummer (2011) “Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions”. Exp. Dermatol., 20, 685-688
• T. Fugmann, B. Borgia, C. Révész, M. Godó, C. Forsblom, P. Hamar, H. Holtöfer, D. Neri, C. Roesli (2011) “Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy” Kidney Int., 80, 272-281
• C.Roesli, T. Fugmann, B. Borgia, C. Schliemann, D. Neri, M. Jucker (2011) “The accessible cerebral vascular proteome in a mouse model of cerebral beta-amyloidosis”. J. Proteomics, 74, 539-546
• K. Frey, A. Zivanovic, K. Schwager, D. Neri (2011) “Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation”. Integr. Biol., 3, 468-478
• A.Baldinger, B.R. Brehm, P. Richter, T. Bossert, K. Gruen, K. Hekmat, H. Kosmehl, D. Neri, H.R. Figulla, A. Berndt, M. Franz (2011) “Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis”. Histochem. Cell. Biol., 135, 427-441
• M. Fiechter, K. Frey, T. Fugmann, P.A. Kaufmann, D. Neri. (2011) “Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies”. Atherosclerosis, 214, 325
• F. Buller, M. Steiner, K. Frey, D. Mircsof, J. Scheuermann, M. Kalisch, P. Bühlmann, C.T. Supuran, D. Neri (2011) “Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds”. ACS Chemical Biol., 6, 336-344